<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721823</url>
  </required_header>
  <id_info>
    <org_study_id>15-6554-BO</org_study_id>
    <nct_id>NCT02721823</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of Stress Reduction and Lifestyle Modification for Ulcerative Colitis</brief_title>
  <acronym>MBMCol</acronym>
  <official_title>Randomized Controlled Trial on the Effect of Stress Reduction and Lifestyle Modification on Disease Activity in Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität Duisburg-Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universität Duisburg-Essen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with ulcerative colitis often suffer significant limitations to their quality of
      life, which are also conditioned by particular stress and psychosocial accompanying symptoms
      of the disease. A multimodal program for stress-reduction and lifestyle-modification has been
      shown to be effective in promoting the quality of life. The study will examine the promotion
      of the quality of life of patients with ulcerative colitis and the positive Influence on
      stress, psychological symptoms and physiological parameters. 92 patients with ulcerative
      colitis will be randomized in an Intervention group and a control group for 10 weeks. The
      primary outcome is the disease-specific quality of life, the secondary outcomes are stress,
      psychological symptoms, inflammatory parameters, disease activity parameters, bowel parameter
      and the microbiome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-specific quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <description>Inflammatory Bowel Disease Questionnaire (IBD-Q)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-specific quality of life</measure>
    <time_frame>48 weeks</time_frame>
    <description>Inflammatory Bowel Disease Questionnaire (IBD-Q)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific quality of life</measure>
    <time_frame>60 weeks</time_frame>
    <description>Inflammatory Bowel Disease Questionnaire (IBD-Q)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific quality of life</measure>
    <time_frame>108 weeks</time_frame>
    <description>Inflammatory Bowel Disease Questionnaire (IBD-Q)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mayo Disease Activity Index (Mayo Score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical Activity Index (CAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity</measure>
    <time_frame>48 weeks</time_frame>
    <description>Mayo Disease Activity Index (Mayo Score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity</measure>
    <time_frame>48 weeks</time_frame>
    <description>Clinical Activity Index (CAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity</measure>
    <time_frame>60 weeks</time_frame>
    <description>Mayo Disease Activity Index (Mayo Score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity</measure>
    <time_frame>60 weeks</time_frame>
    <description>Clinical Activity Index (CAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity</measure>
    <time_frame>108 weeks</time_frame>
    <description>Mayo Disease Activity Index (Mayo Score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity</measure>
    <time_frame>108 weeks</time_frame>
    <description>Clinical Activity Index(CAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic index</measure>
    <time_frame>12 weeks</time_frame>
    <description>Endoscopic-Index (sigmoidoscopy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic index</measure>
    <time_frame>48 weeks</time_frame>
    <description>Endoscopic-Index (sigmoidoscopy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic index</measure>
    <time_frame>60 weeks</time_frame>
    <description>Endoscopic-Index (sigmoidoscopy))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic index</measure>
    <time_frame>108 weeks</time_frame>
    <description>Endoscopic-Index (sigmoidoscopy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histology</measure>
    <time_frame>12 weeks</time_frame>
    <description>Riley Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histology</measure>
    <time_frame>48 weeks</time_frame>
    <description>Riley Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histology</measure>
    <time_frame>60 weeks</time_frame>
    <description>Riley Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histology</measure>
    <time_frame>108 weeks</time_frame>
    <description>Riley Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <description>Short Form (SF) -36 (items) health survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic quality of life</measure>
    <time_frame>48 weeks</time_frame>
    <description>SF-36 health survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic quality of life</measure>
    <time_frame>60 weeks</time_frame>
    <description>SF-36 health survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic quality of life</measure>
    <time_frame>108 weeks</time_frame>
    <description>SF-36 health survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>48 weeks</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>60 weeks</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>108 weeks</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived stress</measure>
    <time_frame>12 weeks</time_frame>
    <description>Perceived Stress Scale (PSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived stress</measure>
    <time_frame>48 weeks</time_frame>
    <description>Perceived Stress Scale (PSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived stress</measure>
    <time_frame>60 weeks</time_frame>
    <description>Perceived Stress Scale (PSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived stress</measure>
    <time_frame>108 weeks</time_frame>
    <description>Perceived Stress Scale (PSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irritable Bowel Syndrome Symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>IBS Severity Scoring System (IBS-SSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irritable Bowel Syndrome Symptoms</measure>
    <time_frame>48 weeks</time_frame>
    <description>IBS Severity Scoring System (IBS-SSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irritable Bowel Syndrome Symptoms</measure>
    <time_frame>60 weeks</time_frame>
    <description>IBS Severity Scoring System (IBS-SSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irritable Bowel Syndrome Symptoms</measure>
    <time_frame>108 weeks</time_frame>
    <description>IBS Severity Scoring System (IBS-SSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemogram</measure>
    <time_frame>12 weeks</time_frame>
    <description>leukocyte, hemoglobin, hematocrit, platelet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemogram</measure>
    <time_frame>48 weeks</time_frame>
    <description>leukocyte, hemoglobin, hematocrit, platelet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemogram</measure>
    <time_frame>60 weeks</time_frame>
    <description>leukocyte, hemoglobin, hematocrit, platelet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemogram</measure>
    <time_frame>108 weeks</time_frame>
    <description>leukocyte, hemoglobin, hematocrit, platelet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood sedimentation rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood sedimentation rate</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood sedimentation rate</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood sedimentation rate</measure>
    <time_frame>108 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>108 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal calprotectin</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal calprotectin</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal calprotectin</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal calprotectin</measure>
    <time_frame>108 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal lactoferrin</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal lactoferrin</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal lactoferrin</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal lactoferrin</measure>
    <time_frame>108 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal polymorphonuclear (PMN)-elastase</measure>
    <time_frame>12 weeks</time_frame>
    <description>faecal polymorphonuclear elastase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal PMN-elastase</measure>
    <time_frame>48 weeks</time_frame>
    <description>faecal polymorphonuclear elastase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal PMN-elastase</measure>
    <time_frame>60 weeks</time_frame>
    <description>faecal polymorphonuclear elastase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal PMN-elastase</measure>
    <time_frame>108 weeks</time_frame>
    <description>faecal polymorphonuclear elastase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal human beta-defensin-2 (hBD-2)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal hBD-2</measure>
    <time_frame>48 weeks</time_frame>
    <description>human beta-defensin-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal hBD-2</measure>
    <time_frame>60 weeks</time_frame>
    <description>human beta-defensin-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>faecal hBD-2</measure>
    <time_frame>108 weeks</time_frame>
    <description>human beta-defensin-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiota</measure>
    <time_frame>12 weeks</time_frame>
    <description>High-throughput 16S ribosomal ribonucleic acid (rRNA) gene sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiota</measure>
    <time_frame>48 weeks</time_frame>
    <description>High-throughput 16S rRNA gene sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiota</measure>
    <time_frame>60 weeks</time_frame>
    <description>High-throughput 16S rRNA gene sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiota</measure>
    <time_frame>108 weeks</time_frame>
    <description>High-throughput 16S rRNA gene sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal permeability</measure>
    <time_frame>12 weeks</time_frame>
    <description>LactoseMonitol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal permeability</measure>
    <time_frame>48 weeks</time_frame>
    <description>LactoseMonitol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal permeability</measure>
    <time_frame>60 weeks</time_frame>
    <description>LactoseMonitol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal permeability</measure>
    <time_frame>108 weeks</time_frame>
    <description>LactoseMonitol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>108 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>lifestyle-modification</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A unique education unit within the scope of 3 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>lifestyle-modification</intervention_name>
    <description>The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of colitis patients.</description>
    <arm_group_label>lifestyle-modification</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 75 years

          -  diagnosis of ulcerative colitis

          -  Currently in remission, remission not longer than 12 months

          -  limited quality of life or increased subjective stress level

        Exclusion Criteria:

          -  Infectious or chronic active ulcerative colitis

          -  Taking glucocorticoids or immunosuppressants within the last 3 months, except stable
             medication using azathioprine

          -  colectomy

          -  serious psychological disorder (for example: major depression, addiction,
             schizophrenia)

          -  serious comorbid somatic disease (for example: diabetes mellitus, oncological disease)

          -  pregnancy

          -  participation in stress reduction program or clinical studies to psychological
             interventions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jost Langhorst, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kliniken Essen-Mitte</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jost Langhorst, Prof. Dr. med.</last_name>
    <phone>020117425012</phone>
    <email>j.langhorst@kliniken-essen-mitte.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte, Knappschafts Krankenhaus</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45276</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jost Langhorst, Prof. Dr.</last_name>
      <phone>49-201-174 25012</phone>
      <email>j.langhorst@kliniken-essen-mitte.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universität Duisburg-Essen</investigator_affiliation>
    <investigator_full_name>Jost Langhorst</investigator_full_name>
    <investigator_title>Medical vice director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

